Gilead pause adds to Merck’s HIV doubts
Could Gilead soon be looking for a new partner for its long-acting project lenacapavir?
The bubble bursts for biotech stocks
After a frothy couple of years, biotechs are no longer seeing big boosts from clinical data.
Daiichi could be rewarded for persisting with Vanflyta
A front-line trial yields a positive result two years after the drug got a US complete response letter.
Atea’s woes grow while other Covid readouts approach
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.
AHA 2021 – Phasebio takes a step towards reversal agent filing
But questions remain around bentracimab’s data package.
